D.I. Vodolazhskiy

Rostov Research Institute of Oncology

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Oleg I. Kit

Rostov Research Institute of Oncology

Natalya N. Timoshkina

Rostov Research Institute of Oncology

КВ

К. В. Двадненко

Centre de Recherche en Sciences et Technologies de l'Information et de la Communication

Evgeniy N. Kolesnikov

Ministry of Health of the Russian Federation

РА

Р. А. Мурашко

Kuban State Medical University

E. M. Frantsiyants

Ministry of Health of the Russian Federation

ЕФ

Е. Ф. Филиппов

Denis S. Kutilin

Ministry of Health of the Russian Federation

Anna V. Antonets

Rostov State Medical University

G.V. Gudkov

Cooperative Institutions

Rostov Research Institute of Oncology

Ministry of Health of the Russian Federation

Russian Academy of Sciences

Institute of Oncology NN Petrov

National Medical Research Center of Cardiology

Saint Petersburg State Pediatric Medical University

Research Medical Center

Rostov State Medical University

Research Centre for Medical Genetics

Academy of Medical Sciences

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

Possibilities of using dendritic cell vaccine in treatment of radiation injury of the bladder

Cancer Urology (2019)

Oleg I. Kit Anna P. Menshenina L. Ya. Rozenko T Moiseenko E. M. Frantsyants

Background . Radiation therapy for patients with cervical and endometrial cancer is often associated with the development of radiation cystitis which is treated mainly symptomatically. Objective was the rationale for dendritic cell vaccines in the treatment of the bladder damage after radiation therapy. Materials and methods . The treatment effectiveness of late radiation damage to the bladder in 26 oncogynecologic patients after chemoradiotherapy was analyzed in the article. Results . The effectiveness of 25.000.000 autologous dendritic cells vaccine introduced into all the tops of the rhombus of Michaelis for 5 cycles with 2-week intervals was proved. Mucosal erosions, ulcerous defects and telangiectasia during dendritic cell therapy were managed in 100, 81.8 and 78.6 % of cases, respectively, while in control — in 66.7, 50 and 30 % of cases, respectively (p <0.05). One of the mechanisms of action of dendritic cell vaccines in the treatment of radiation injuries may comprise a high phenotypic plasticity of dendritic cells and macrophages and their ability to regulate inflammatory and anti-inflammatory functions and regenerate and repair damaged tissues. Conclusion . The results of treatment for radiation cystitis resistant to the standard anti-inflammatory therapies demonstrate the obvious benefits of immunotherapy.

10.17650/1726-9776-2018-14-4-118-123

Cite

Citations (0)

Clinical Manifestations of Egfr Gene Mutations in Patients with Adenocarcinoma of the Lung Among Inhabitants of the South Russian Region

Annals of Oncology (2014)

D.I. Vodolazhskiy Igor A. Leyman Anna V. Antonets Yury N. Lazutin К. В. Двадненко

10.1093/annonc/mdu358.56

Cite

Citations (0)

EXPERIENCE OF DENDRITIC CELL VACCINE DESIGN FOR CERVICAL CANCER TREATMENT

D.I. Vodolazhskiy К. В. Двадненко

На основании морфологических и иммунофенотипических критериев показана возможность получе-ния зрелых ДК методом их генерации из МНК крови доноров и больных. К 9-м суткам культивирования в присутствии GM-CSF, IL-4 и TNF-α, а также лизата культуры HeLa происходит утрата мембранных мар-керов моноцитов (СD14, СD1а) при нарастании количества клеток, экспрессирующих маркеры ДК (СD83, СD86), что сопровождается характерными для ДК морфологическими признаками (приобретением много-угольной, отростчатой и веретеновидной формы). В этот срок наблюдения маркеры зрелых ДК экспрес-сированы на 99,6 % (СD83) и 99,9 % (СD86) клеток. Добавление лизата культуры HeLa в последние 2 дня культивирования ДК не угнетает их дифференцировку, а напротив, потенциально может являться фактором ее стимуляции. Ключевые слова

HeLa

Source

Cite

Citations (0)

Distribution of EGFR Mutations in 10,607 Russian Patients with Lung Cancer

Molecular Diagnosis & Therapy (2016)

Evgeny N. Imyanitov Ирина Демидова M. Gordiev М. Л. Филипенко Tatyana V. Kekeyeva

10.1007/s40291-016-0213-4

Cite

Citations (39)

ABERRANT METHYLATION OF THE PROMOTER OF APC, CDH13 AND MGMT GENES IN COLORECTAL CANCER PATIENTS

Siberian Journal of Oncology (2016)

Oleg I. Kit D.I. Vodolazhskiy К. В. Двадненко Irina Yu. Efimova Elena Oleynikova

Aberrant methylation of gene promoter regions is the main epigenetic change characterizing colorectal cancer. Methylation levels of 42 CpG-sites of promoter regions of the MGMT, APC and CDH13 genes in colorectal cancer were studied in comparison with methylation levels of the adjacent normal tissue in 25 patients. Pyrosequencing showed an increase in methylation levels of promoter regions of the MGMT, APC and CDH13 genes in tumor samples by 3 to 5 times. These tumor samples were screened for activating SNP-mutations in the KRAS (40 %), NRAS (0 %) and BRAF (0 %) oncogenes. SNP-mutations in the KRAS gene were accompanied by hypermethylation of one or more promoters of the studied genes. Association of this epigenetic index with tumor metastasis was proved. The data on an increase in methylation of the promoter regions of oncosupressor genes can be used as sensitive prognostic markers of progression and metastasis of colorectal cancer.

CpG site

10.21294/1814-4861-2016-15-2-48-55

Cite

Citations (3)

Epigenetic markers of esophageal cancer: DNA methylation

Biomeditsinskaya Khimiya (2016)

Oleg I. Kit D.I. Vodolazhskiy Evgeniy N. Kolesnikov Natalya N. Timoshkina

Adenocarcinoma and squamous cell carcinoma are the most common types of esophageal cancer with a constant tendency to increase the incidence of growth on the background of the high mortality, which makes particularly the development of new biomarkers that complement and improve the early diagnosis of this disease. Despite the impressive number of studies in routine clinical practice is used only marker of esophageal cancer - ERBB2/HER2 status. This review summarizes data on the identified epigenetic markers of the aberrant methylation of the genome, which may be useful for early detection of esophageal cancer, prognosis estimation and / or prediction of response to treatment. The development of new high-tech genome-wide screening, such as beadarray and immunoprecipitation sequencing method used for the wideband genotyping, but for the analysis of transcriptome and metilom, provides a comprehensive picture of genetic and epigenetic changes during tumorigenesis. Note the need to verify the most biomarkers on large representative samples for the development of valid diagnostic panels, suitable for large-scale screening of risk groups.Adenokartsinoma i ploskokletochnyĭ rak otnosiatsia k naibolee rasprostranennym tipam zlokachestvennykh novoobrazovaniĭ pishchevoda s postoiannoĭ tendentsieĭ k rostu zabolevaemosti na fone vysokoĭ smertnosti, chto delaet osobo aktual'nym poisk novykh biomarkerov, dopolniaiushchikh i uluchshaiushchikh ranniuiu diagnostiku étogo zabolevaniia. Nesmotria na vnushitel'noe kolichestvo issledovaniĭ, v rutinnoĭ klinicheskoĭ praktike ispol'zuetsia edinstvennyĭ marker raka pishchevoda – status ERBB2/HER2. V nastoiashchem obzore obobshcheny dannye ob épigeneticheskikh markerakh, kharakterizuiushchikh aberrantnoe metilirovanie genoma, kotorye mogut okazat'sia poleznymi dlia rannego obnaruzheniia raka pishchevoda, prognoza i/ili predskazaniia otveta na lechenie. Razvitie novykh vysokoproizvoditel'nykh tekhnologiĭ polnogenomnogo skrininga, takikh kak “BeadChip array” i immunopretsipitatsiia c posleduiushchim sekvenirovaniem, ispol'zuemykh ne tol'ko dlia polnogenomnogo genotipirovaniia, no i dlia analiza transkriptoma i metiloma, pozvoliaet poluchit' kompleksnye kartiny geneticheskikh i épigeneticheskikh izmeneniĭ v khode onkogeneza.

Surgical oncology

10.18097/pbmc20166205520

Cite

Citations (6)

Changes in CpG methylation of APC, CDH13, MLH1, MGMT, P16 and RASSF1A in gastric adenocarcinoma

Annals of Oncology (2018)

Natalya N. Timoshkina Oleg I. Kit D.I. Vodolazhskiy Н. В. Солдаткина Y. A. Gevorkyan

MLH1

CpG site

Stomach cancer

10.1093/annonc/mdy282.032

Cite

Citations (2)

Epigenetic markers of esophageal cancer: DNA methylation

Biochemistry (Moscow) Supplement Series B Biomedical Chemistry (2017)

Oleg I. Kit D.I. Vodolazhskiy Evgeniy N. Kolesnikov Natalya N. Timoshkina

Epigenomics

10.1134/s1990750817010048

Cite

Citations (5)

TRANSCRIPTIONAL PROFILE OF CANCER-TESTICULAR ANTIGENS IN PATIENTS WITH BREAST CANCER

Medical Immunology (Russia) (2018)

D.I. Vodolazhskiy Denis S. Kutilin Kh. A. Mogushkova Oleg I. Kit

To identify new effective targets for immunotherapy of breast cancer, based on cancer-testis antigens (CTA), the associations were studied between CTA gene expression, clinical and pathological characteristics of breast cancer. Therefore, the aim of the study was to perform screening of CTAs specific to breast tissue tumors (luminal types A and B) based on assessment of the transcriptional profile of cancer-testis genes in the patients of different ages. To evaluate these relations, paired surgical biopsies (normal and tumor) of breast tissue of 32 patients (64 samples) aged 38-86 years were used. Relative expression of 16 genetic loci (MAGEA1, MAGEA2, MAGEA3, MAGEA4, MAGEB1, MAGEB2, GAGE1, GAGE3, GAGE4, MAGEC1, BAGE, XAGE3, NY-ESO1, SSX2, SYCP1 and PRAME1) was determined by the RT-qPCR. It was found that the transcriptional profile of CTA differs in different age groups of patients (at the age of < 55 years, overexpression of MAGEA3 was noted; after 55 years, MAGEA1, MAGEB1, BAGE, NY-ESO1, GAGE1 and GAGE3 were more expressed). In the luminal type A cancer, overexpression of MAGEA1, MAGEA2, MAGEA4, MAGEB1, MAGEB2, GAGE3, GAGE4, MAGEC1 and PRAME1, whereas in B type cancer, the genes with increased expression were not detected. These differences should be considered when planning immunotherapy, can be used as biomarkers for both breast cancer as clinical entity, and, in particular, for its individual subtypes.

CA 15-3

10.15789/1563-0625-2018-3-383-390

Cite

Citations (5)

KRAS Gene Mutations and Gender Differences in Colorectal Cancer

International Journal of Biomedicine (2015)

Oleg I. Kit D.I. Vodolazhskiy Yuriy А. Gevorkyan Н В Солдаткина

The aim of this study was to investigate the frequency and spectrum of KRAS mutations in men and women with colorectal cancer (CRC), and an impact of KRAS-mutation status on the clinical and morphological features of CRC.The study included 303 patients (168/55.4% women and 135/44.6%men) with CRC T2-4N0-2M0-1.We defined 7 KRAS SNP-mutations (G12D, G12A, G12R, G12C, G12S, G12V and G13D) located within codons 12 and 13 using Bio-Rad real-time thermal cyclers CFX96 and Real-Time-PCR-KRAS-7M Kit.The frequency of KRAS mutations was 35.6% in the CRC patients with a predominant presence of G>A transitions.The KRAS codon 12 and 13 mutations are predictive of poor prognosis The KRAS-mutated CRC has clinical features in view of the gender differences.KRAS-mutation status is a promising predictive biomarker of personalized treatment.

SNP

10.21103/article5(1)_cr2

Cite

Citations (6)